Pricing

BeyondSpring Inc (BYSI)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Lan Huang
Employees:
80
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, SUITE 410, FLORHAM PARK, NJ, 07932
646-528-4184
Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available